OR WAIT null SECS
April 18, 2023
Moderna and Merck reported that a combination therapy involving pembrolizumab and an mRNA demonstrated a 44% reduction in recurrence or death in cancer patients compared to non-combination treatments.
AbbVie’s RINVOQ has received European Commission approval for the treatment of moderately to severely active Crohn’s disease.
Gamida Cell’s therapy is meant to reduce the risk of infection following stem cell transplantation.
Integrated systems combine functions.
April 14, 2023
Avid Bioservices has launched new CGMP mammalian cell manufacturing suites at its Myford, Calif., facility.
FDA has granted fast track designation to Caribou Biosciences for its allogeneic CAR-T cell therapy for relapsed or refractory multiple myeloma.
Under this partnership, the two companies will develop bioprinted tissue therapeutics for diabetes and obesity.
The construction will expand Catalent’s clinical supply facility in Schorndorf, Germany.
Ginkgo Bioworks has acquired StrideBio's AAV capsid discovery and engineering platform and has formed a partnership with WARF for development of next-gen cell therapies.
The acquisition of Cell Systems will bolster AnaBios’ portfolio of human tissue and cells for use in drug discovery.